UA98312C2 - Progesterone receptor antagonists - Google Patents

Progesterone receptor antagonists

Info

Publication number
UA98312C2
UA98312C2 UAA200906032A UAA200906032A UA98312C2 UA 98312 C2 UA98312 C2 UA 98312C2 UA A200906032 A UAA200906032 A UA A200906032A UA A200906032 A UAA200906032 A UA A200906032A UA 98312 C2 UA98312 C2 UA 98312C2
Authority
UA
Ukraine
Prior art keywords
receptor antagonists
progesterone receptor
general formula
hydrogen atom
relates
Prior art date
Application number
UAA200906032A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ульрике Фурманн
Аня Шмидт
Арвед Клеве
Орлин Петроф
Гуннар Гарке
Штефан Прюс
Маргарете Брудни-Кльоппель
Антье Роттманн
Райнер Хассельманн
Маркус Шульце-Мосгау
Карстен Мьоллер
Original Assignee
Байер Фарма Акциенгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезелльшафт filed Critical Байер Фарма Акциенгезелльшафт
Publication of UA98312C2 publication Critical patent/UA98312C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение касается антагонистов прогестеронового рецептора общей формулы I:,формула Iв которой R1 может быть атомом водорода и R2 гидроксильной группой или R1 и R2 вместе могут быть оксогруппой.
UAA200906032A 2006-11-15 2007-11-14 Progesterone receptor antagonists UA98312C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006054535A DE102006054535A1 (de) 2006-11-15 2006-11-15 Progesteronrezeptorantagonisten
PCT/EP2007/009997 WO2008058767A1 (en) 2006-11-15 2007-11-14 Progesterone receptor antagonists

Publications (1)

Publication Number Publication Date
UA98312C2 true UA98312C2 (en) 2012-05-10

Family

ID=39243738

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200906032A UA98312C2 (en) 2006-11-15 2007-11-14 Progesterone receptor antagonists

Country Status (41)

Country Link
US (1) US8053426B2 (ru)
EP (1) EP2081951B1 (ru)
JP (1) JP5260537B2 (ru)
KR (1) KR101494914B1 (ru)
CN (1) CN101541823B (ru)
AR (1) AR063813A1 (ru)
AT (1) ATE465169T1 (ru)
AU (1) AU2007321848B2 (ru)
BR (1) BRPI0718409A2 (ru)
CA (1) CA2669767C (ru)
CL (1) CL2007003266A1 (ru)
CO (1) CO6180443A2 (ru)
CY (1) CY1110671T1 (ru)
DE (2) DE102006054535A1 (ru)
DK (1) DK2081951T3 (ru)
EA (1) EA017038B1 (ru)
EC (1) ECSP099337A (ru)
ES (1) ES2343915T3 (ru)
GT (1) GT200900128A (ru)
HK (1) HK1136302A1 (ru)
HN (1) HN2009000997A (ru)
HR (1) HRP20100366T1 (ru)
IL (1) IL198650A (ru)
JO (1) JO2672B1 (ru)
MA (1) MA30990B1 (ru)
MX (1) MX2009005212A (ru)
NO (1) NO20092284L (ru)
NZ (1) NZ576927A (ru)
PA (1) PA8755801A1 (ru)
PE (1) PE20081409A1 (ru)
PL (1) PL2081951T3 (ru)
PT (1) PT2081951E (ru)
RS (1) RS51369B (ru)
SI (1) SI2081951T1 (ru)
SV (1) SV2009003260A (ru)
TN (1) TN2009000185A1 (ru)
TW (1) TW200831109A (ru)
UA (1) UA98312C2 (ru)
UY (1) UY30718A1 (ru)
WO (1) WO2008058767A1 (ru)
ZA (1) ZA200904150B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP2868320A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for the treatment of human cells
CA2966753A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
WO2017053793A1 (en) 2015-09-25 2017-03-30 Arno Therapeutics, Inc. Methods of making onapristone intermediates
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
WO2017165315A1 (en) * 2016-03-21 2017-09-28 Arno Therapeutics, Inc. Onapristone metabolite compositions and methods
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
CN86102502B (zh) * 1986-08-29 1988-06-22 上海市计划生育科学研究所 11，17位双取代δ4，9-雌甾二烯化合物的合成方法
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19535572B4 (de) * 1994-09-14 2007-02-01 Schering Ag Verfahren zur Herstellung von 17 α-Fluor-steroid-ketonen
CA2205897A1 (en) * 1994-11-22 1996-05-30 Malcolm Cecil Pike Compositions and methods for contraception and for treatment of benign gynecological disorders
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) * 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
DE19929715A1 (de) * 1999-06-24 2000-12-28 Schering Ag 11ß-langkettig-substituierte Estratriene, Verfahren zur Herstellung , pharmazeutische Präparate, die diese 11ß-langkettig-substituierten Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
MXPA03002953A (es) * 2000-10-18 2003-08-07 Schering Ag Inhibicion del factor de crecimiento dependiente de las celulas de tumor.
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DK1501859T3 (da) 2002-05-03 2006-03-06 Schering Ag 17 alfa-fluoralkyl- 11 beta-benzaldoxim-steroider, fremgangsmåde til fremstilling heraf, farmaceutiske præparater indeholdende disse steroider samt deres anvendelse til fremstilling af lægemidler
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten

Also Published As

Publication number Publication date
AR063813A1 (es) 2009-02-18
BRPI0718409A2 (pt) 2013-12-17
PT2081951E (pt) 2010-07-01
DK2081951T3 (da) 2010-08-09
JO2672B1 (en) 2012-06-17
AU2007321848B2 (en) 2013-09-19
ATE465169T1 (de) 2010-05-15
MA30990B1 (fr) 2009-12-01
TN2009000185A1 (en) 2010-10-18
HN2009000997A (es) 2011-10-19
TW200831109A (en) 2008-08-01
WO2008058767A1 (en) 2008-05-22
CN101541823A (zh) 2009-09-23
EA017038B1 (ru) 2012-09-28
CO6180443A2 (es) 2010-07-19
CL2007003266A1 (es) 2008-07-04
KR101494914B1 (ko) 2015-02-23
PL2081951T3 (pl) 2010-09-30
CY1110671T1 (el) 2015-06-10
SI2081951T1 (sl) 2010-08-31
US20080200440A1 (en) 2008-08-21
IL198650A0 (en) 2010-02-17
EP2081951A1 (en) 2009-07-29
CN101541823B (zh) 2012-10-03
IL198650A (en) 2012-05-31
ZA200904150B (en) 2010-11-24
RS51369B (en) 2011-02-28
EP2081951B1 (en) 2010-04-21
HK1136302A1 (en) 2010-06-25
JP5260537B2 (ja) 2013-08-14
AU2007321848A1 (en) 2008-05-22
PE20081409A1 (es) 2008-12-05
PA8755801A1 (es) 2009-08-26
EA200900635A1 (ru) 2009-12-30
HRP20100366T1 (hr) 2010-07-31
ES2343915T3 (es) 2010-08-12
KR20090079995A (ko) 2009-07-22
SV2009003260A (es) 2009-12-14
US8053426B2 (en) 2011-11-08
UY30718A1 (es) 2008-07-03
JP2010509386A (ja) 2010-03-25
NZ576927A (en) 2012-01-12
CA2669767C (en) 2014-04-01
DE602007006040D1 (de) 2010-06-02
CA2669767A1 (en) 2008-05-22
MX2009005212A (es) 2009-05-27
GT200900128A (es) 2012-02-01
DE102006054535A1 (de) 2008-05-21
ECSP099337A (es) 2009-06-30
NO20092284L (no) 2009-08-13

Similar Documents

Publication Publication Date Title
TN2009000185A1 (en) Progesterone receptor antagonists
CU23818A3 (es) Antagonistas del receptor de progesterona
PL2069332T3 (pl) Związki azetydynowe jako antagoniści receptorów oreksynowych
MX2010007849A (es) Antagonista del receptor opoide selectivo kappa.
PL2164847T3 (pl) Związki 3-azabicyklo[3.3.0]oktanowe
MX2011011127A (es) 3-azabiciclo[4.1.0] heptanos usados como antagonistas de orexina.
MX2010007867A (es) Composiciones de limpieza personal concentradas.
EP2525790A4 (en) METHODS AND COMPOSITIONS FOR DISORDERS ASSOCIATED WITH CELL PROLIFERATION
MX2011013117A (es) Peptidos especificos del receptor de melanocortina.
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
MX351611B (es) Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
MX2009010515A (es) Antagonistas del receptor opioide periferico y usos de los mismos.
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
WO2010068282A3 (en) Compositions and methods for synthesis of hydrogen fuel
TN2009000040A1 (en) 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin ii receptor antagonists
EP2464597A4 (en) HYDROGEN PRODUCTION WITH MAGNESIUM- AND SILICY-CONTAINING COMPOSITIONS
TW200613317A (en) Steroid prodrugs with androgenic action
ZA200902338B (en) Uses of fischer-tropsch fuel compositions
NZ598247A (en) Compositions and methods for treating parkinson’s disease
DOP2009000112A (es) Antagonistas del receptor de progesterona
IN2014CN00817A (ru)
AU323043S (en) Birdcage roof
MX2008011602A (es) Genes inducidos in vivo de mycobacterium tuberculosis.
UA33402U (ru) Использование антагониста рецепторов интерлейкина-1 в качестве средства с антигипоксическим действием
UA40770U (ru) Применение антагониста рецепторов интерлейкина-1 в качестве кардиопротекторного средства